Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | APLNR | P35414 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15778053 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25858433 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL6899604 | 0.83 | APLNR (0.54) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL15776462 | 0.79 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16249319 | 0.79 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL23896104 | 0.79 | CHRNB2 (0.37) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL14031505 | 0.77 | CHRNB2 (0.39) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL10084365 | 0.77 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL8213986 | 0.77 | TP53 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL9960236 | 0.76 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113490668-B | Compounds and compositions for the treatment of diseases associated with APJ receptor activity | 安娜普尔纳生物股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12060351-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2024-08-13 | — | — | US | disclosed |
| CN-112566915-B | Thiadiazole IRAK4 inhibitors | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | GILEAD SCIENCES, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | SHOUTI INC. | 2023-06-01 | — | — | US | disclosed |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-12-22 | — | — | US | disclosed |
| US-20220125787-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | ANNAPURNA BIO, INC. | 2022-04-28 | — | — | US | disclosed |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | GILEAD SCIENCES, INC. | 2022-03-31 | — | — | US | disclosed |
| US-11046686-B2 | Thiadiazole IRAK4 compounds | GILEAD SCIENCES, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| CN-112566915-A | Thiadiazole IRAK4 inhibitor | 吉利德科学公司 | 2021-03-26 | — | — | CN | disclosed |
| US-20200079769-A1 | THIADIAZOLE IRAK4 COMPOUNDS | GILEAD SCIENCES, INC. | 2020-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046686-B2 | Thiadiazole IRAK4 compounds | IRAK4, IRAK3, IRAK2 | CHRNB2 4550/4885CHRNA4 2645/4885CHRNB4 3291/4885 |
| US-20220098187-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | CHRNB2 4634/4885CHRNA4 3221/4885CHRNB4 3659/4885 |
| US-12060351-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | CHRNB2 4634/4885CHRNA4 3221/4885CHRNB4 3659/4885 |
| US-20220125787-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | CHRNB2 2126/4885CHRNA4 2888/4885CHRNB4 2990/4885 |
| US-20200079769-A1 | THIADIAZOLE IRAK4 COMPOUNDS | IRAK4, IRAK3, IRAK2 | CHRNB2 4550/4885CHRNA4 2645/4885CHRNB4 3291/4885 |
| US-11702414-B2 | Thiadiazole IRAK4 inhibitors | IRAK4, IRAK3, IRAK1 | CHRNB2 4634/4885CHRNA4 3221/4885CHRNB4 3659/4885 |
| US-20230165854-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY | APLNR, AGTR1, AGTR2 | CHRNB2 2126/4885CHRNA4 2888/4885CHRNB4 2990/4885 |
| US-20220402910-A1 | THIADIAZOLE IRAK4 INHIBITORS | IRAK4, IRAK3, IRAK1 | CHRNB2 4634/4885CHRNA4 3221/4885CHRNB4 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.